Progress in clinical herb-drug interactions mediated by drug metabolism- related genes

Abstract

Abstract: Herbal medicines can be used for both prescriptions or food supplements with a wide range of applications.Inductive or inhibitive effects of herbal medicines on cytochrome P450 enzymes and drug transporters is the main mechanism that mediates herb-drug interactions and produces clinical toxicity. Herbal medicines could alter plasma exposure of substrate drugs for drug metabolizing enzymes or transporters by influencing the expressions and functions of drug metabolizing enzymes or transporters, perhaps resulting in unexpected clinical toxicity or therapeutic failure and leading to herb-drug interactions with clinical importance.Moreover, herb-drug interactions are in accordance with the gene-dosage rule, and therefore have genetic interindividual differences. Research progress of the clinical herb-drug interactions and related pharmacogenomics studies mediated by drug metabolism-related genes are reviewed in this article.

Key words: Herb medicine, HERb-drug interaction, CYP450 enzyme, Drug transporter, Pharmacogenomics, Nuclear receptor

CLC Number:

GAO Li-chen, ZHANG Wei, LIU Zhao-qian, FAN Lan, ZHOU Hong-hao. Progress in clinical herb-drug interactions mediated by drug metabolism- related genes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 346-351.

References

[1] Phapale PB, Kim SD, Lee HW, et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus[J]. Clin Pharmacol Ther, 2010, 87(4):426-436.
[2] Herranz JL. Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy[J]. Rev Neurol, 2006, 10(43):43-49.
[3] Chan AL, Leung HW, Wu JW, et al. Risk of hemorrhage associated with co-prescriptions for Ginkgo biloba and antiplatelet or anticoagulant drugs[J]. J Altern Complement Med, 2011, 17(6):513-517.
[4] Yin OQP, Tomlinson B, Waye MMY, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole[J]. Pharmacogenetics, 2004, 14(12):841-850.
[5] Fan L, Wang G, Wang LS, et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole[J]. Acta Pharmacol Sin, 2007, 28 (10):1685-1692.
[6] Suzanne H, Janny GP, Jochem L, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole[J]. Pharmacogenet Genom, 2004, 75(3):191-197.
[7] Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme[J]. Br J Clin Pharmacol, 2009, 67(2):255-261.
[8] Xu H, Williams KM, Liauw WS, et al. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide[J]. Br J Pharmacol, 2008, 153(7):1579-1586.
[9] Yang LJ, Fan L, Liu ZQ, et al. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes[J]. Eur J Clin Pharmacol, 2009, 65(6):601-608.
[10] Zheng J, Chen B, Jiang B, et al. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo[J]. Arch Pharm Res, 2010, 33(2):243-246.
[11] Tu JH, He YJ, Chen Y, et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans[J]. Eur J Clin Pharmacol, 2010, 66(8):805-810.
[12] Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes[J]. Clin Pharmacol Ther, 2005, 77(5):415-426.
[13] Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans[J]. Eur J Clin Pharmacol, 2012, 68(2):213-217.
[14] Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004, 75(1):89 -100.
[15] 陈欣,李玉珍,方翼, 等. CYP3A4代谢药物的特点及其多态性的研究现状[J]. 中国药房, 2010, 21(22):2097-2099.
[16] Mai I, Stormer E, Bauer S, et al. Impact of St John`s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients[J]. Nephrol Dial Transplant, 2003,8 (4): 819-822.
[17] 韩璐,刘洁. CYP2D6基因多态性及对药物代谢的影响[J]. 中国临床药理学与治疗学, 2011, 16 (1): 105-110.
[18] Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs[J]. J Clin Pharmacol, 2007, 47(5) :566-578.
[19] 刘艳,尹又,陈尧,等.人类孕烷受体遗传变异对遗传药理学和药物代谢的影响[J].中国临床药理学与治疗学, 2007, 12(8):845-849.
[20] Na DH, Ji HY, Park EJ, et al. Evaluation of Metabolism-Mediated Herb-Drug Interactions[J].Chinese Pharmacological Bulletin, 2011, 34(11):1829-1842.
[21] Meyer Zu, Schwabedissen HE, Böttcher K, et al. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1[J]. Hepatology,2010, 52(5):1797-807.